Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Dec 3, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K filing on 12/3, likely with news in the press release.
AI Summary
Innate Pharma SA filed a Form 6-K on December 3, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or operational details beyond the reporting of the press release.
Why It Matters
This filing indicates Innate Pharma is providing an update to the market, likely through the attached press release, which could contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate indication of significant financial or operational changes within the filing itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- December 3, 2024 (date) — Filing Date
- 001-39084 (other) — Commission File Number
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release dated December 3, 2024, as required for foreign private issuers.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
When was the press release attached to this filing dated?
The press release attached to this filing is dated December 3, 2024.
Does this filing include an annual report on Form 20-F?
The filing indicates that Innate Pharma SA files annual reports under cover of Form 20-F, marked with an 'X'.
What is the principal executive office address for Innate Pharma SA?
The principal executive office address for Innate Pharma SA is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-12-03 06:03:10
Filing Documents
- a6k-iphx241203.htm (6-K) — 8KB
- exhibit991-241203.htm (EX-99.1) — 24KB
- 0001598599-24-000094.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date December 3, 2024 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive officer